300 related articles for article (PubMed ID: 24476585)
1. The fluorescent two-hybrid assay to screen for protein-protein interaction inhibitors in live cells: targeting the interaction of p53 with Mdm2 and Mdm4.
Yurlova L; Derks M; Buchfellner A; Hickson I; Janssen M; Morrison D; Stansfield I; Brown CJ; Ghadessy FJ; Lane DP; Rothbauer U; Zolghadr K; Krausz E
J Biomol Screen; 2014 Apr; 19(4):516-25. PubMed ID: 24476585
[TBL] [Abstract][Full Text] [Related]
2. A yeast two-hybrid system for the screening and characterization of small-molecule inhibitors of protein-protein interactions identifies a novel putative Mdm2-binding site in p53.
Wong JH; Alfatah M; Sin MF; Sim HM; Verma CS; Lane DP; Arumugam P
BMC Biol; 2017 Nov; 15(1):108. PubMed ID: 29121928
[TBL] [Abstract][Full Text] [Related]
3. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.
Pellegrino M; Mancini F; Lucà R; Coletti A; Giacchè N; Manni I; Arisi I; Florenzano F; Teveroni E; Buttarelli M; Fici L; Brandi R; Bruno T; Fanciulli M; D'Onofrio M; Piaggio G; Pellicciari R; Pontecorvi A; Marine JC; Macchiarulo A; Moretti F
Cancer Res; 2015 Nov; 75(21):4560-72. PubMed ID: 26359458
[TBL] [Abstract][Full Text] [Related]
4. Implementation of a 220,000-compound HCS campaign to identify disruptors of the interaction between p53 and hDM2 and characterization of the confirmed hits.
Dudgeon DD; Shinde S; Hua Y; Shun TY; Lazo JS; Strock CJ; Giuliano KA; Taylor DL; Johnston PA; Johnston PA
J Biomol Screen; 2010 Aug; 15(7):766-82. PubMed ID: 20639499
[TBL] [Abstract][Full Text] [Related]
5. Discovery of MDM2-p53 and MDM4-p53 protein-protein interactions small molecule dual inhibitors.
Espadinha M; Lopes EA; Marques V; Amaral JD; Dos Santos DJVA; Mori M; Daniele S; Piccarducci R; Zappelli E; Martini C; Rodrigues CMP; Santos MMM
Eur J Med Chem; 2022 Nov; 241():114637. PubMed ID: 35961068
[TBL] [Abstract][Full Text] [Related]
6. A cell-based high-throughput assay for the screening of small-molecule inhibitors of p53-MDM2 interaction.
Li J; Zhang S; Gao L; Chen Y; Xie X
J Biomol Screen; 2011 Apr; 16(4):450-6. PubMed ID: 21471462
[TBL] [Abstract][Full Text] [Related]
7. The p53-Mdm2 interaction and the E3 ligase activity of Mdm2/Mdm4 are conserved from lampreys to humans.
Coffill CR; Lee AP; Siau JW; Chee SM; Joseph TL; Tan YS; Madhumalar A; Tay BH; Brenner S; Verma CS; Ghadessy FJ; Venkatesh B; Lane DP
Genes Dev; 2016 Feb; 30(3):281-92. PubMed ID: 26798135
[TBL] [Abstract][Full Text] [Related]
8. A simple cell-based HTS assay system to screen for inhibitors of p53-Hdm2 protein-protein interactions.
Lundholt BK; Heydorn A; Bjørn SP; Praestegaard M
Assay Drug Dev Technol; 2006 Dec; 4(6):679-88. PubMed ID: 17199506
[TBL] [Abstract][Full Text] [Related]
9. Adenoviral E1A targets Mdm4 to stabilize tumor suppressor p53.
Li Z; Day CP; Yang JY; Tsai WB; Lozano G; Shih HM; Hung MC
Cancer Res; 2004 Dec; 64(24):9080-5. PubMed ID: 15604276
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous measurement of p53:Mdm2 and p53:Mdm4 protein-protein interactions in whole cells using fluorescence labelled foci.
Frosi Y; Inoue K; Ramlan SR; Lane DP; Watanabe T; Brown CJ
Sci Rep; 2019 Nov; 9(1):17933. PubMed ID: 31784573
[TBL] [Abstract][Full Text] [Related]
11. Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2.
Dudgeon DD; Shinde SN; Shun TY; Lazo JS; Strock CJ; Giuliano KA; Taylor DL; Johnston PA; Johnston PA
Assay Drug Dev Technol; 2010 Aug; 8(4):437-58. PubMed ID: 20662736
[TBL] [Abstract][Full Text] [Related]
12. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
[TBL] [Abstract][Full Text] [Related]
13. Assessing the Efficacy of Mdm2/Mdm4-Inhibiting Stapled Peptides Using Cellular Thermal Shift Assays.
Tan BX; Brown CJ; Ferrer FJ; Yuen TY; Quah ST; Chan BH; Jansson AE; Teo HL; Nordlund P; Lane DP
Sci Rep; 2015 Jul; 5():12116. PubMed ID: 26159518
[TBL] [Abstract][Full Text] [Related]
14. Stapled peptides with improved potency and specificity that activate p53.
Brown CJ; Quah ST; Jong J; Goh AM; Chiam PC; Khoo KH; Choong ML; Lee MA; Yurlova L; Zolghadr K; Joseph TL; Verma CS; Lane DP
ACS Chem Biol; 2013 Mar; 8(3):506-12. PubMed ID: 23214419
[TBL] [Abstract][Full Text] [Related]
15. An Application of Fit Quality to Screen MDM2/p53 Protein-Protein Interaction Inhibitors.
Xue X; Bao G; Zhang HQ; Zhao NY; Sun Y; Zhang Y; Wang XL
Molecules; 2018 Dec; 23(12):. PubMed ID: 30513790
[No Abstract] [Full Text] [Related]
16. Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions.
Barakat K; Mane J; Friesen D; Tuszynski J
J Mol Graph Model; 2010 Feb; 28(6):555-68. PubMed ID: 20056466
[TBL] [Abstract][Full Text] [Related]
17. Using BRET to study chemical compound-induced disruptions of the p53-HDM2 interactions in live cells.
Mazars A; Fåhraeus R
Biotechnol J; 2010 Apr; 5(4):377-84. PubMed ID: 20235143
[TBL] [Abstract][Full Text] [Related]
18. Peptides and peptidomimetics in the p53/MDM2/MDM4 circuitry - a patent review.
Teveroni E; Lucà R; Pellegrino M; Ciolli G; Pontecorvi A; Moretti F
Expert Opin Ther Pat; 2016 Dec; 26(12):1417-1429. PubMed ID: 27603098
[TBL] [Abstract][Full Text] [Related]
19. LC-MS/MS-based targeted proteomics quantitatively detects the interaction between p53 and MDM2 in breast cancer.
Zhang W; Zhong T; Chen Y
J Proteomics; 2017 Jan; 152():172-180. PubMed ID: 27826076
[TBL] [Abstract][Full Text] [Related]
20. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
Sirous H; Chemi G; Campiani G; Brogi S
Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]